Organovo reports preliminary unaudited cash and net cash utilization for Q4 2025; expects to meet Nasdaq listing requirements.

On April 02, 2025, Organovo Holdings, Inc. (Nasdaq: ONVO) announced its focus on developing innovative treatments for inflammatory bowel disease (IBD). They disclosed preliminary unaudited cash amounts for the fiscal year ending March 31, 2025, as well as net cash utilization for the fourth fiscal quarter of 2025. Full fiscal second-quarter financial results are anticipated to be released during the week of June 9-13, 2025. The company also projected that it anticipates fulfilling the listing requirements on the Nasdaq Capital Market, given that its common stock has maintained trading levels above the necessary $1.00 minimum bid price.